A Phase III, Randomized, Controlled, Open-Label, Multicenter, Parallel Group Study Using Provisions for Exception From Informed Consent Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P Injection [Polymerized Human Hemoglobin (Pyridoxylated), PolyHeme(R)] When Used to Treat Patients in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Prehospital Setting
Latest Information Update: 28 Aug 2020
Price :
$35 *
At a glance
- Drugs Human haemoglobin (Primary)
- Indications Anaemia; Haemorrhagic shock
- Focus Registrational; Therapeutic Use
- Sponsors Northfield Laboratories
- 28 Aug 2020 Results presented in the PubMed Central
- 28 Aug 2020 New trial record